 | • レポートコード：B-GIR08C4257 • 出版社/出版日：GlobalInfoResearch / 2019年8月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、138ページ • 納品方法：Eメール • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、抗癌薬におけるパクリタキセル・類似体の世界市場について調べ、まとめました。種類別セグメントは、パクリタキセル、ドセタキセル、リポソームパクリタキセル、タンパク質結合パクリタキセル等、用途別セグメントは、化学工業、自動車工業、食品飲料工業、建築・建設工業、製薬・ヘルスケア工業、電気・電子工業、等に区分しました。抗癌薬におけるパクリタキセル・類似体の世界市場概観、企業動向、企業別抗癌薬におけるパクリタキセル・類似体シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析（北米、ヨーロッパ、アジア等）、主要国分析（日本、中国、アメリカ等）データなどの情報が含まれています。 ・抗癌薬におけるパクリタキセル・類似体の市場概観 ・抗癌薬におけるパクリタキセル・類似体の企業概要（事業概要、製品種類、販売量、価格、売上、市場シェア等） ・抗癌薬におけるパクリタキセル・類似体の企業別販売動向、市場シェア、市場集中度、競争動向 ・抗癌薬におけるパクリタキセル・類似体の世界市場規模 ・抗癌薬におけるパクリタキセル・類似体の北米市場分析（アメリカ、カナダ、メキシコ等） ・抗癌薬におけるパクリタキセル・類似体のアメリカ市場規模推移 ・抗癌薬におけるパクリタキセル・類似体のカナダ市場規模推移 ・抗癌薬におけるパクリタキセル・類似体のメキシコ市場規模推移 ・抗癌薬におけるパクリタキセル・類似体のヨーロッパ市場分析（ドイツ、イギリス、ロシア、フランス、イタリア等） ・抗癌薬におけるパクリタキセル・類似体のドイツ市場規模推移 ・抗癌薬におけるパクリタキセル・類似体のイギリス市場規模推移 ・抗癌薬におけるパクリタキセル・類似体のロシア市場規模推移 ・抗癌薬におけるパクリタキセル・類似体のアジア太平洋市場分析（日本、中国、韓国、インド、東南アジア等） ・抗癌薬におけるパクリタキセル・類似体の日本市場規模推移 ・抗癌薬におけるパクリタキセル・類似体の中国市場規模推移 ・抗癌薬におけるパクリタキセル・類似体の韓国市場規模推移 ・抗癌薬におけるパクリタキセル・類似体のインド市場規模推移 ・抗癌薬におけるパクリタキセル・類似体の東南アジア市場規模推移 ・抗癌薬におけるパクリタキセル・類似体の南米市場分析（ブラジル、アルゼンチン等） ・抗癌薬におけるパクリタキセル・類似体の中東・アフリカ市場分析（サウジアラビア、UAE、南アフリカ等） ・抗癌薬におけるパクリタキセル・類似体の種類別分析/販売量、売上、市場シェア（パクリタキセル、ドセタキセル、リポソームパクリタキセル、タンパク質結合パクリタキセル） ・抗癌薬におけるパクリタキセル・類似体の用途別分析/市場規模（化学工業、自動車工業、食品飲料工業、建築・建設工業、製薬・ヘルスケア工業、電気・電子工業、） ・抗癌薬におけるパクリタキセル・類似体の市場予測2019年-2024年（地域別予測、種類別予測、用途別予測） ・抗癌薬におけるパクリタキセル・類似体の販売チャネル・代理店・貿易業者・ディーラー分析 |
Scope of the Report:
The global Paclitaxel and Its Analogue in Anticarcinoma Drugs market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Paclitaxel and Its Analogue in Anticarcinoma Drugs.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Paclitaxel and Its Analogue in Anticarcinoma Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Paclitaxel and Its Analogue in Anticarcinoma Drugs market by product type and applications/end industries.
Market Segment by Companies, this report covers
Bristol-Myers Squibb
Celgene Corporation
Hospira
Biological E.
Taj Accura
Khandelwal Laboratories
Luye Pharma
Beijing Youcare
Beijing Union
Haiyao
Chuntch
Hengrui Medicine
Sanofi
Qilu Pharma
Shenzhen Main Luck Pharma
Jiangsu Aosaikang Pharma
CSPC Pharmaceutical
Aosaikang Pharm
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Paclitaxel
Docetaxel
Liposome Paclitaxel
Protein-bound Paclitaxel
Market Segment by Applications, can be divided into
Ovarian Cancer
Breast Cancer
Cervical Cancer
Pancreatic Cancer
Non-small Cell Lung Cancer
Other
Table of Contents
1 Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Overview
1.1 Product Overview and Scope of Paclitaxel and Its Analogue in Anticarcinoma Drugs
1.2 Classification of Paclitaxel and Its Analogue in Anticarcinoma Drugs by Types
1.2.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Comparison by Types (2019-2024)
1.2.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Types in 2018
1.2.3 Paclitaxel
1.2.4 Docetaxel
1.2.5 Liposome Paclitaxel
1.2.6 Protein-bound Paclitaxel
1.3 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market by Application
1.3.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Ovarian Cancer
1.3.3 Breast Cancer
1.3.4 Cervical Cancer
1.3.5 Pancreatic Cancer
1.3.6 Non-small Cell Lung Cancer
1.3.7 Other
1.4 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market by Regions
1.4.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Paclitaxel and Its Analogue in Anticarcinoma Drugs Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Paclitaxel and Its Analogue in Anticarcinoma Drugs Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Paclitaxel and Its Analogue in Anticarcinoma Drugs Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Paclitaxel and Its Analogue in Anticarcinoma Drugs Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Paclitaxel and Its Analogue in Anticarcinoma Drugs Status and Prospect (2014-2024)
1.5 Global Market Size of Paclitaxel and Its Analogue in Anticarcinoma Drugs (2014-2024)
2 Manufacturers Profiles
2.1 Bristol-Myers Squibb
2.1.1 Business Overview
2.1.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Bristol-Myers Squibb Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.2 Celgene Corporation
2.2.1 Business Overview
2.2.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Celgene Corporation Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.3 Hospira
2.3.1 Business Overview
2.3.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Hospira Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.4 Biological E.
2.4.1 Business Overview
2.4.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Biological E. Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.5 Taj Accura
2.5.1 Business Overview
2.5.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Taj Accura Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.6 Khandelwal Laboratories
2.6.1 Business Overview
2.6.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Khandelwal Laboratories Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.7 Luye Pharma
2.7.1 Business Overview
2.7.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Luye Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.8 Beijing Youcare
2.8.1 Business Overview
2.8.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Beijing Youcare Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.9 Beijing Union
2.9.1 Business Overview
2.9.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Beijing Union Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.10 Haiyao
2.10.1 Business Overview
2.10.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Haiyao Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.11 Chuntch
2.11.1 Business Overview
2.11.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Chuntch Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.12 Hengrui Medicine
2.12.1 Business Overview
2.12.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Hengrui Medicine Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.13 Sanofi
2.13.1 Business Overview
2.13.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Sanofi Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.14 Qilu Pharma
2.14.1 Business Overview
2.14.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Qilu Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.15 Shenzhen Main Luck Pharma
2.15.1 Business Overview
2.15.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Shenzhen Main Luck Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.16 Jiangsu Aosaikang Pharma
2.16.1 Business Overview
2.16.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Jiangsu Aosaikang Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.17 CSPC Pharmaceutical
2.17.1 Business Overview
2.17.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 CSPC Pharmaceutical Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
2.18 Aosaikang Pharm
2.18.1 Business Overview
2.18.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Aosaikang Pharm Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
3 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Competition, by Players
3.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Paclitaxel and Its Analogue in Anticarcinoma Drugs Players Market Share
3.2.2 Top 10 Paclitaxel and Its Analogue in Anticarcinoma Drugs Players Market Share
3.3 Market Competition Trend
4 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size by Regions
4.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Market Share by Regions
4.2 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
4.3 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
4.5 South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
5 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Countries
5.1 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Countries (2014-2019)
5.2 USA Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
5.3 Canada Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
5.4 Mexico Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
6 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Countries
6.1 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Countries (2014-2019)
6.2 Germany Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
6.3 UK Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
6.4 France Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
6.5 Russia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
6.6 Italy Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Countries
7.1 Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Countries (2014-2019)
7.2 China Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
7.3 Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
7.4 Korea Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
7.5 India Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
8 South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Countries
8.1 South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Countries (2014-2019)
8.2 Brazil Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
8.3 Argentina Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
8.4 Colombia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Paclitaxel and Its Analogue in Anticarcinoma Drugs by Countries
9.1 Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Countries (2014-2019)
9.2 Saudi Arabia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
9.3 UAE Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
9.4 Egypt Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
9.5 Nigeria Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
9.6 South Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
10 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Segment by Type
10.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Market Share by Type (2014-2019)
10.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Forecast by Type (2019-2024)
10.3 Paclitaxel Revenue Growth Rate (2014-2024)
10.4 Docetaxel Revenue Growth Rate (2014-2024)
10.5 Liposome Paclitaxel Revenue Growth Rate (2014-2024)
10.6 Protein-bound Paclitaxel Revenue Growth Rate (2014-2024)
11 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Segment by Application
11.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Application (2014-2019)
11.2 Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Forecast by Application (2019-2024)
11.3 Ovarian Cancer Revenue Growth (2014-2019)
11.4 Breast Cancer Revenue Growth (2014-2019)
11.5 Cervical Cancer Revenue Growth (2014-2019)
11.6 Pancreatic Cancer Revenue Growth (2014-2019)
11.7 Non-small Cell Lung Cancer Revenue Growth (2014-2019)
11.8 Other Revenue Growth (2014-2019)
12 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size Forecast (2019-2024)
12.1 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Size Forecast (2019-2024)
12.2 Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Forecast by Regions (2019-2024)
12.3 North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Forecast (2019-2024)
12.4 Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Forecast (2019-2024)
12.6 South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
Figure Paclitaxel and Its Analogue in Anticarcinoma Drugs Picture
Table Product Specifications of Paclitaxel and Its Analogue in Anticarcinoma Drugs
Table Global Paclitaxel and Its Analogue in Anticarcinoma Drugs and Revenue (Million USD) Market Split by Product Type
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Types in 2018
Figure Paclitaxel Picture
Figure Docetaxel Picture
Figure Liposome Paclitaxel Picture
Figure Protein-bound Paclitaxel Picture
Table Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) by Application (2014-2024)
Figure Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Applications in 2018
Figure Ovarian Cancer Picture
Figure Breast Cancer Picture
Figure Cervical Cancer Picture
Figure Pancreatic Cancer Picture
Figure Non-small Cell Lung Cancer Picture
Figure Other Picture
Table Global Market Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) Comparison by Regions 2014-2024
Figure North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) and Growth Rate (2014-2024)
Figure Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) and Growth Rate (2014-2024)
Figure Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) and Growth Rate (2014-2024)
Figure South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) and Growth Rate (2014-2024)
Figure Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) and Growth Rate (2014-2024)
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) and Growth Rate (2014-2024)
Table Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table Bristol-Myers Squibb Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Bristol-Myers Squibb Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Celgene Corporation Basic Information, Manufacturing Base and Competitors
Table Celgene Corporation Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Celgene Corporation Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Hospira Basic Information, Manufacturing Base and Competitors
Table Hospira Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Hospira Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Biological E. Basic Information, Manufacturing Base and Competitors
Table Biological E. Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Biological E. Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Taj Accura Basic Information, Manufacturing Base and Competitors
Table Taj Accura Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Taj Accura Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Khandelwal Laboratories Basic Information, Manufacturing Base and Competitors
Table Khandelwal Laboratories Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Khandelwal Laboratories Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Luye Pharma Basic Information, Manufacturing Base and Competitors
Table Luye Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Luye Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Beijing Youcare Basic Information, Manufacturing Base and Competitors
Table Beijing Youcare Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Beijing Youcare Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Beijing Union Basic Information, Manufacturing Base and Competitors
Table Beijing Union Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Beijing Union Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Haiyao Basic Information, Manufacturing Base and Competitors
Table Haiyao Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Haiyao Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Chuntch Basic Information, Manufacturing Base and Competitors
Table Chuntch Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Chuntch Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Hengrui Medicine Basic Information, Manufacturing Base and Competitors
Table Hengrui Medicine Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Hengrui Medicine Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Sanofi Basic Information, Manufacturing Base and Competitors
Table Sanofi Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Sanofi Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Qilu Pharma Basic Information, Manufacturing Base and Competitors
Table Qilu Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Qilu Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Shenzhen Main Luck Pharma Basic Information, Manufacturing Base and Competitors
Table Shenzhen Main Luck Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Shenzhen Main Luck Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Jiangsu Aosaikang Pharma Basic Information, Manufacturing Base and Competitors
Table Jiangsu Aosaikang Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Jiangsu Aosaikang Pharma Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table CSPC Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table CSPC Pharmaceutical Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table CSPC Pharmaceutical Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Aosaikang Pharm Basic Information, Manufacturing Base and Competitors
Table Aosaikang Pharm Paclitaxel and Its Analogue in Anticarcinoma Drugs Type and Applications
Table Aosaikang Pharm Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue, Gross Margin and Market Share (2017-2018)
Table Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) by Players (2014-2019)
Table Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Players (2014-2019)
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Players in 2017
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Players in 2018
Figure Global Top 5 Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share in 2018
Figure Global Top 10 Players Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share in 2018
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) and Growth Rate (%) (2014-2019)
Table Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) by Regions (2014-2019)
Table Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Regions (2014-2019)
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Regions (2014-2019)
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Regions in 2018
Figure North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Table North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Countries (2014-2019)
Table North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Countries (2014-2019)
Figure North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Countries (2014-2019)
Figure North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Countries in 2018
Figure USA Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure Canada Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure Mexico Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Table Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) by Countries (2014-2019)
Figure Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Countries (2014-2019)
Figure Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Countries in 2018
Figure Germany Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure UK Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure France Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure Russia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure Italy Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Table Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) by Countries (2014-2019)
Figure Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Countries (2014-2019)
Figure Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Countries in 2018
Figure China Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure Japan Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure Korea Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure India Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure Southeast Asia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Table South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Countries (2014-2019)
Table South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Countries (2014-2019)
Figure South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Countries (2014-2019)
Figure South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Countries in 2018
Figure Brazil Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure Argentina Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure Colombia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Table Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) by Countries (2014-2019)
Table Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share by Countries in 2018
Figure Saudi Arabia Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure UAE Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure Egypt Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure Nigeria Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Figure South Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue and Growth Rate (2014-2019)
Table Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) by Type (2014-2019)
Table Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Type (2014-2019)
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Type (2014-2019)
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Type in 2018
Table Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Forecast by Type (2019-2024)
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share Forecast by Type (2019-2024)
Figure Global Paclitaxel Revenue Growth Rate (2014-2019)
Figure Global Docetaxel Revenue Growth Rate (2014-2019)
Figure Global Liposome Paclitaxel Revenue Growth Rate (2014-2019)
Figure Global Protein-bound Paclitaxel Revenue Growth Rate (2014-2019)
Table Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue by Application (2014-2019)
Table Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Application (2014-2019)
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Application (2014-2019)
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Share by Application in 2018
Table Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Forecast by Application (2019-2024)
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Market Share Forecast by Application (2019-2024)
Figure Global Ovarian Cancer Revenue Growth Rate (2014-2019)
Figure Global Breast Cancer Revenue Growth Rate (2014-2019)
Figure Global Cervical Cancer Revenue Growth Rate (2014-2019)
Figure Global Pancreatic Cancer Revenue Growth Rate (2014-2019)
Figure Global Non-small Cell Lung Cancer Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) and Growth Rate Forecast (2019-2024)
Table Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue (Million USD) Forecast by Regions (2019-2024)
Figure Global Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Share Forecast by Regions (2019-2024)
Figure North America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Forecast (2019-2024)
Figure Europe Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Forecast (2019-2024)
Figure Asia-Pacific Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Forecast (2019-2024)
Figure South America Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Forecast (2019-2024)
Figure Middle East and Africa Paclitaxel and Its Analogue in Anticarcinoma Drugs Revenue Market Forecast (2019-2024)
骨がん治療薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Bone cancer can begin in any bone in the body, but it most commonly affects the pelvis or the long bones in the arms and legs. Bone cancer is rare, making up less than 1 percent of all cancers. In fact, noncancerous bone tumors are much more common than cancerous ones. Scope of the Report: The globa…- 世界の骨髄異形成症候群（MDS）薬市場：市場規模・現状・予測 Myelodysplastic syndrome is caused by mutation of one or more genes that control development of blood cells. It is one of the most common malignant hematological diseases that affects five out of every 100,000 people in U.S. annually. An estimated 60,000 people in U.S. live with MDS, and approximate…
- 世界の非カタプレキシーナルコレプシー薬市場：市場規模・現状・予測 In 2018, the global Non Cataplexy Narcolepsy Drugs market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2019-2025. This report focuses on the global Non Cataplexy Narcolepsy Drugs status, future forecast, growth opportunity, key market and key…
- 胃癌薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Stomach Cancer Drugs are used to treat stomach malignancies, or cancerous growths. Depending on the technology it cans classification into Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy and Others. Scope of the Report: The global Stomach Cancer Drugs market is val…
- メトプロロール配合薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Metoprolol Combination Drugs market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in Chi…